21+
Age Verification
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
IGF-1 LR3 (Long [Arg3] Insulin-Like Growth Factor-1) is an 83-amino acid modified analogue of endogenous IGF-1, engineered with two key structural modifications: a glutamate-to-arginine substitution at position 3 (Arg3) and a 13-amino acid N-terminal extension peptide. These modifications were designed to significantly reduce binding affinity for IGF-binding proteins (IGFBPs) while preserving full IGF-1 receptor activation in in-vitro assays.
Published research has demonstrated that the reduced IGFBP binding of LR3 results in a substantially higher proportion of free, unbound peptide in experimental systems compared to native IGF-1. This structural characteristic has made IGF-1 LR3 a widely utilized research tool for studying IGF-1 receptor signaling pathways, including the PI3K/Akt and MAPK/ERK cascades, independent of the modulatory effects of binding proteins.
AXOM IGF-1 LR3 is manufactured under strict cGMP-equivalent protocols and verified to ≥99% purity via reverse-phase HPLC. Each lot is accompanied by a Certificate of Analysis documenting identity, purity, peptide content, and endotoxin levels. Available in 1mg lyophilized format for research use only.
Engineered with Arg3 substitution and 13-amino acid N-terminal extension — 83 amino acids total, designed for enhanced research utility in IGF-1 receptor studies.
Structural modifications confer significantly reduced affinity for IGF-binding proteins, enabling study of IGF-1R signaling independent of IGFBP modulation in laboratory assays.
≥99% HPLC-verified purity with full COA documentation. Every lot independently tested by third-party analytical laboratories.
Foundational characterization study of the LR3 analogue describing its production, structural verification, and reduced IGF-binding protein affinity. Established the key pharmacological distinction between LR3 and native IGF-1 with detailed binding assay data and in-vivo activity profiles.
Comparative study evaluating the activity profiles of native IGF-1 versus the LR3 analogue in controlled preclinical models. Demonstrated the enhanced bioavailability of LR3 attributable to its reduced sequestration by IGF-binding proteins in experimental systems.
Comprehensive review of the IGF binding protein family and their modulatory effects on IGF activity. Provides the biochemical rationale for the LR3 modification strategy, detailing how IGFBP evasion alters the pharmacological profile of IGF-1 analogues in research applications.
| Product Name | IGF-1 LR3 (Long [Arg3] IGF-1) |
| Synonyms | Long R3 IGF-1, LR3-IGF-1, Long Arginine IGF-1 |
| CAS Number | 946870-92-4 |
| Molecular Formula | C400H625N111O115S9 |
| Molecular Weight | ~9,117.44 Da |
| Sequence Length | 83 amino acids |
| Modifications | Arg3 substitution + 13-AA N-terminal extension |
| Receptor Target | IGF-1 Receptor (IGF-1R) |
| Purity | ≥99% (Reverse-Phase HPLC) |
| Form | Lyophilized white powder |
| Available Size | 1mg |
| SKU | LTF-IG-1 |
| Solubility | Soluble in sterile water, bacteriostatic water (0.1M acetic acid recommended for stock solutions) |
| Endotoxin | <1 EU/μg (LAL method) |
| Certification | COA included with every order |
| Intended Use | For research and laboratory use only |
IGF-1 LR3 is supplied as a lyophilized powder and should be reconstituted with sterile bacteriostatic water (BAC water) or 0.1M acetic acid for research applications.
All orders ship within the continental United States via USPS or UPS. Peptides are shipped at ambient temperature — lyophilized peptides are stable during transit. Free shipping on orders over $250.
